SHR 1139
Alternative Names: SHR-1139Latest Information Update: 15 May 2025
At a glance
- Originator Guangdong Hengrui Pharmaceutical
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
Most Recent Events
- 13 Mar 2025 Guangdong Hengrui Pharmaceutical plans a phase II trial for Plaque Psoriasis in China (Injection), in March 2025 (NCT06875934)